The Pandemic Hurt, But EY Expects More Biopharma Deal-Making In 2021

Life Sciences M&A Was Almost Half Of 2019’s Record

 
• By Joseph Haas
fire embers
Biopharma companies have ample deal-making "firepower" to deploy in 2021

More from Deals

More from Business